Literature DB >> 31864728

High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Relieving Dyspnea in Emergency Palliative Patients With Do-Not-Intubate Status: A Randomized Crossover Study.

Onlak Ruangsomboon1, Thawonrat Dorongthom1, Tipa Chakorn2, Apichaya Monsomboon1, Nattakarn Praphruetkit1, Chok Limsuwat1, Usapan Surabenjawong1, Sattha Riyapan1, Tanyaporn Nakornchai1, Wansiri Chaisirin1.   

Abstract

STUDY
OBJECTIVE: Palliative patients often visit the emergency department (ED) with respiratory distress during their end-of-life period. The goal of management is alleviating dyspnea and providing comfort. High-flow nasal cannula may be an alternative oxygen-delivering method for palliative patients with do-not-intubate status. We therefore aim to compare the efficacy of high-flow nasal cannula with conventional oxygen therapy in improving dyspnea of palliative patients with do-not-intubate status who have hypoxemic respiratory failure in the ED.
METHODS: This randomized, nonblinded, crossover study was conducted with 48 palliative patients aged 18 years or older with do-not-intubate status who presented with hypoxemic respiratory failure to the ED of Siriraj Hospital, Bangkok, Thailand. The participants were randomly allocated to conventional oxygen therapy for 60 minutes, followed by high-flow nasal cannula for 60 minutes (n=24) or vice versa (n=24). The primary outcome was modified Borg scale score. The secondary outcomes were numeric rating scale score of dyspnea and vital signs.
RESULTS: Intention-to-treat analysis included 44 patients, 22 in each group. Baseline mean modified Borg scale score was 7.6 (SD 2.2) (conventional oxygen therapy first) and 8.2 (SD 1.8) (high-flow nasal cannula first). At 60 minutes, mean modified Borg scale score in patients receiving conventional oxygen therapy and high-flow nasal cannula was 4.9 (standard of mean 0.3) and 2.9 (standard of mean 0.3), respectively (mean difference 2.0; 95% confidence interval 1.4 to 2.6). Results for the numeric rating scale score of dyspnea were similar to those for the modified Borg scale score. Respiratory rates were lower with high-flow nasal cannula (mean difference 5.9; 95% confidence interval 3.5 to 8.3), and high-flow nasal cannula was associated with a significantly lower first-hour morphine dose.
CONCLUSION: High-flow nasal cannula was superior to conventional oxygen therapy in reducing the severity of dyspnea in the first hour of treatment in patients with do-not-intubate status and hypoxemic respiratory failure.
Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31864728     DOI: 10.1016/j.annemergmed.2019.09.009

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

1.  High-Flow Oxygen and High-Flow Air for Dyspnea in Hospitalized Patients with Cancer: A Pilot Crossover Randomized Clinical Trial.

Authors:  David Hui; Farley Hernandez; Diana Urbauer; Saji Thomas; Zhanni Lu; Ahmed Elsayem; Eduardo Bruera
Journal:  Oncologist       Date:  2020-12-15

2.  Effect of heated humidified high-flow nasal cannula (HFNC) oxygen therapy in dyspnea patients with advanced cancer, a randomized controlled clinical trial.

Authors:  Zhaoning Xu; Pingping Li; Chi Zhang; Dedong Ma
Journal:  Support Care Cancer       Date:  2022-08-19       Impact factor: 3.359

3.  ERS International Congress 2021: highlights from the Respiratory Intensive Care Assembly.

Authors:  Aileen Kharat; Carla Ribeiro; Berrin Er; Christoph Fisser; Daniel López-Padilla; Foteini Chatzivasiloglou; Leo M A Heunks; Maxime Patout; Rebecca F D'Cruz
Journal:  ERJ Open Res       Date:  2022-05-23

Review 4.  Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians.

Authors:  Arianne K Baldomero; Anne C Melzer; Nancy Greer; Brittany N Majeski; Roderick MacDonald; Eric J Linskens; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2021-04-27       Impact factor: 25.391

5.  Nasal High-flow Oxygen Versus Conventional Oxygen Therapy for Acute Severe Asthma Patients: A Pilot Randomized Controlled Trial.

Authors:  Onlak Ruangsomboon; Chok Limsuwat; Nattakarn Praphruetkit; Apichaya Monsomboon; Tipa Chakorn
Journal:  Acad Emerg Med       Date:  2020-12-22       Impact factor: 3.451

Review 6.  Use of nasal high flow oxygen during acute respiratory failure.

Authors:  Jean-Damien Ricard; Oriol Roca; Virginie Lemiale; Amanda Corley; Jens Braunlich; Peter Jones; Byung Ju Kang; François Lellouche; Stefano Nava; Nuttapol Rittayamai; Giulia Spoletini; Samir Jaber; Gonzalo Hernandez
Journal:  Intensive Care Med       Date:  2020-09-08       Impact factor: 17.440

7.  Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study.

Authors:  Takafumi Koyauchi; Yuzo Suzuki; Kazuki Sato; Hironao Hozumi; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Koshi Yokomura; Shiro Imokawa; Hidenori Nakamura; Tatsuya Morita; Takafumi Suda
Journal:  Respir Res       Date:  2022-04-04

Review 8.  Noninvasive Ventilation in Treatment of Respiratory Failure-Related COVID-19 Infection: Review of the Literature.

Authors:  Bushra Mina; Alexander Newton; Vijay Hadda
Journal:  Can Respir J       Date:  2022-08-31       Impact factor: 2.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.